Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).

Pieter Sonneveld, Sonja Zweegman, Hans E. Johnsen, Roman Hajek, Francesco Di Raimondo, Antonio Palumbo, Rossella Troia, Bronno van der Holt, Lucia Pantani, Francesca Gay, Ruth Wester, Christoph Driessen, Ka Lung Wu, Meral Beksac, Heinz Ludwig, Meletios A. Dimopoulos, Ulf-Henrik Mellqvist, Annalisa Pezzi, Michele Cavo, Maria Teresa Petrucci

Research output: Contribution to journalArticleAcademicpeer-review


8000Background: The role of upfront ASCT for newly diagnosed (ND) MM (NDMM) patients (pts) has been questioned in the novel agent era. Methods: A phase 3 study was designed to compare [random (R) 1] 4 cycles of bortezomib-melphalan-prednisone (VMP) vs high-dose melphalan (HDM) and single or double ASCT (this latter limited to centers applying a tandem ASCT policy) as intensification therapy following induction with bortezomib-cyclophosphamide-dexamethasone and subsequent collection of peripheral blood stem cells. Consolidation therapy with bortezomib-lenalidomide-dexamethasone vs no consolidation (R2) was planned after VMP and HDM, followed by lenalidomide maintenance until progression or toxicity in both treatment arms. Primary study end point was progression-free survival (PFS) from R1. A first prespecified interim analysis was performed in January 2016 when at least 33% of the required events had been observed. Results are herein reported. Results: From February 2011 through April 2014, 1503 pts aged ≤65 years with symptomatic NDMM were registered. Of these, 1308 pts were eligible for R1 and 1266 who were randomized (1:1 ratio; stratification by ISS stage) to VMP (512 pts) or HDM (1±2 ASCT) (754 pts) were analyzed. Median follow up from R1 was 24 months. PFS was significantly prolonged in pts randomized to HDM (HR=0.76; 95% CI=0.61-0.94; P=0.010), a benefit retained across predefined pt subgroups, including those with revised ISS stage III (HR=0.52; CI=0.32-0.84; P=0.008) and high-risk cytogenetics [t(4;14) ± del(17p) ± del(1p) ± 1q gain] (HR=0.72; CI=0.54-0.97; P=0.028). Superior rate of ≥ very good partial response was observed with HDM (84%) vs VMP (74%) (odds ratio=1.90; CI=1.42-2.54; P
Original languageEnglish
Pages (from-to)8000-8000
Number of pages1
JournalJournal of clinical oncology
Issue number15_suppl
Publication statusPublished - 6 Sept 2018

Cite this